abstract |
Disclosed is a novel therapy for malignant multiple myeloma (MM) of B cells characterized by abnormal clonal proliferation of plasma cells in the bone marrow. A chimeric antigen receptor (CAR) capable of specifically recognizing cell surface glycoprotein CS1, which is a tumor associated antigen (TAA) on MM cells, is disclosed. Also disclosed are immune effector cells such as T cells or natural killer (NK) cells that have been genetically engineered to express these CARs. Accordingly, a method for providing anti-tumor immunity to a subject with MM is also disclosed, comprising adoptive transfer of immune effector cells of the present disclosure that have been genetically engineered to express the CAR of the present disclosure. [Selection figure] None |